NEURAL TRANSPLANTATION IN THE TREATMENT OF PATIENTS WITH PARKINSON’S DISEASE

Informations projet

TRANSEURO

N° de convention de subvention: 242003

Projet clôturé

Date de début 1 Janvier 2010

Date de fin 30 Juin 2016

Financé au titre de

• Specific Programme "Cooperation": Health

Coût total € 16 142 794,19

Contribution de l’UE € 11 994 095,00

Coordonné par

THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE
United Kingdom

Objectif

There are currently no cures for Parkinson's disease (PD) but one of the most effective reparative therapies in patients to date has been with allotransplants of dopamine (DA) neuroblasts obtained from fetal ventral mesencephalic (VM) tissue. However, this cell transplantation approach has given inconsistent results, with some patients doing extremely well and coming off anti-PD medication for years, whilst others have shown no or only modest clinical improvements, and in some cases also developed severe, off-state graft-induced dyskinesias (GIDs). The reasons behind this heterogeneity of outcomes, and the emergence of GIDs in particular, need to be better understood, not least in the perspective of the rapid advances that are now being made in the development of stem-cell based therapies. There is therefore an urgent need to revisit the trials that have already been done with fetal VM tissue in PD patients, with the expectation that a critical reassessment can form the basis for an optimised and more standardised procedure that will translate into more consistently efficacious transplants with minimal side-effects. Over the last two years a group of international experts, including the key investigators of the previous European and North American trials, has been re-examining the outcome of these trials as well as reviewing the results obtained from recent and ongoing animal experimental studies, and identified a number of weaknesses that may explain the inconsistent outcome in previous trials. As a result of these discussions, the group has agreed to join forces in a new round of experimental work and cell therapy trials in PD, based on a new jointly developed protocol where all these factors are taken into account. In the first instance fetal VM tissue containing mesencephalic DA neuroblasts will be used, with the expectation that this will pave the way for bigger trials using dopaminergic neurons derived from stem cells.

Champ scientifique

• medical and health sciences › basic medicine › pharmacology and pharmacy › pharmaceutical drugs
• medical and health sciences › medical biotechnology › cells technologies › stem cells
• medical and health sciences › basic medicine › neurology › parkinson
• medical and health sciences › clinical medicine › transplantation

Programme(s)

• FP7-HEALTH - Specific Programme "Cooperation": Health

Thème(s)

• HEALTH-2009-1.4-1 - Cell therapy for tissue and organs

Appel à propositions

FP7-HEALTH-2009-single-stage
Voir d’autres projets de cet appel

Régime de financement

CP-IP - Large-scale integrating project

Coordinateur

THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE

• Contribution de l’UE: € 3 808 371,15
• Adresse: TRINITY LANE THE OLD SCHOOLS ; CB2 1TN Cambridge ; Royaume-Uni
• Région: East of England › East Anglia › Cambridgeshire CC
• Type d’activité: Higher or Secondary Education Establishments
• Contact administratif: Renata Schaeffer (Mr.)
• Coût total: Aucune donnée

Participants (14)

MAX IV Laboratory, Lund University

Suède

• Contribution de l’UE: € 982 706,24
• Adresse: Paradisgatan 5c ; 22100 LUND
• Région: Södra Sverige › Sydsverige › Skåne län
• Type d’activité: Higher or Secondary Education Establishments
• Contact administratif: Anders Björklund (Prof.)
• Coût total: Aucune donnée

CARDIFF UNIVERSITY

Royaume-Uni

• Contribution de l’UE: € 1 114 980,00
• Adresse: NEWPORT ROAD 30 36 ; CF24 0DE Cardiff
• Région: Wales › East Wales › Cardiff and Vale of Glamorgan
• Type d’activité: Higher or Secondary Education Establishments
• Contact administratif: Nick Bodycombe (Mr.)
• Coût total: Aucune donnée

IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE

Royaume-Uni

• Contribution de l’UE: € 636 024,40
• Adresse: SOUTH KENSINGTON CAMPUS EXHIBITION ROAD ; SW7 2AZ LONDON
• Région: London › Inner London — West › Westminster
• Type d’activité: Higher or Secondary Education Establishments
• Contact administratif: Mike Robinson (Mr.)
• Coût total: Aucune donnée

UNIVERSITY COLLEGE LONDON

• Contribution de l’UE: € 369 600,00
• Adresse: GOWER STREET ; WC1E 6BT LONDON
• Type d’activité: Higher or Secondary Education Establishments
• Contact administratif: Greta Borg-Carbott (Ms.)
• Coût total: Aucune donnée

UNIVERSITAETSKLINIKUM FREIBURG

Allemagne

• Contribution de l’UE: € 2 005 726,00
• Adresse: HUGSTETTER STRASSE 49 ; 79106 Freiburg
• Région: Baden-Württemberg › Freiburg › Freiburg im Breisgau, Stadtkreis
• Type d’activité: Higher or Secondary Education Establishments
• Contact administratif: Gerhard Henninger (Mr.)
• Coût total: Aucune donnée

LIFE SCIENCE GOVERNANCE INSTITUTE

Autriche

• Contribution de l’UE: € 213 664,98
• Adresse: Schottenfeldgasse 29 ; 1070 vienna
• Type d’activité: Public bodies (excluding Research Organisations and Secondary or Higher Education Establishments)
• Contact administratif: Herbert Gottweis (Prof.)
• Coût total: Aucune donnée

ASSISTANCE PUBLIQUE HOPITAUX DE PARIS

France

• Contribution de l’UE: € 756 201,00
• Adresse: 55 BOULEVARD DIDEROT ; 75012 Paris
• Région: Ile-de-France › Ile-de-France › Val-de-Marne
• Type d’activité: Research Organisations
• Contact administratif: Stephane Palfi (Prof.)
• Coût total: Aucune donnée

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE

France

• Contribution de l’UE: € 25 849,30
• Adresse: RUE DE TOLBIAC 101 ; 75654 Paris
• Région: Ile-de-France › Ile-de-France › Paris
• Type d’activité: Research Organisations
• Contact administratif: Annick Bertault (Ms.)
• Coût total: Aucune donnée

DANDO WEISS & COLUCCI LIMITED

Participation terminée

Royaume-Uni

• Contribution de l’UE: € 310 162,14
• Adresse: LOWER BRISTOL ROAD MINERVA HOUSE ; BA2 9ER BATH
• Type d’activité: Private for-profit entities (excluding Higher or Secondary Education Establishments)
• Contact administratif: Isabelle Weiss (Dr.)
• Coût total: Aucune donnée

LIFE TECHNOLOGIES LIMITED

Royaume-Uni

• Contribution de l’UE: € 173 600,00
• Adresse: Fountain Drive 3 ; PA4 9RF Paisley
• Type d’activité: Private for-profit entities (excluding Higher or Secondary Education Establishments)
• Contact administratif: Alan Dion (Mr.)
• Coût total: Aucune donnée

Inomed Medizintechnik GmbH

Allemagne

• Contribution de l’UE: € 73 800,00
• Adresse: Tullastrasse 5a ; 79331 Teningen
• Type d’activité: Private for-profit entities (excluding Higher or Secondary Education Establishments)
• Contact administratif: Rudi Mattmueller (Mr.)
• Coût total: Aucune donnée

CAMBRIDGE COGNITION LIMITED

Royaume-Uni

• Contribution de l’UE: € 61 650,00
• Adresse: TUNBRIDGE COURT TUNBRIDGE LANE, BOTTISHAM CAMBS ; CB25 9TU Cambridge
• Région: East of England › East Anglia › Cambridgeshire CC
• Type d’activité: Private for-profit entities (excluding Higher or Secondary Education Establishments)
• Contact administratif: Andrew Blackwell (Dr.)
• Coût total: Aucune donnée

REGION SKANE

Suède

• Contribution de l’UE: € 671 759,99
• Adresse: REGION SKANE ; 291 89 Kristianstad
• Région: Södra Sverige › Sydsverige › Skåne län
• Type d’activité: Public bodies (excluding Research Organisations and Secondary or Higher Education Establishments)
• Contact administratif: Håkan Fornander (Mr.)
• Coût total: Aucune donnée

IMANOVA LIMITED

Royaume-Uni

• Contribution de l’UE: € 789 999,80
• Adresse: BURLINGTON DANES BUILDING, IMPERIAL COLLEGE LONDON HAMMERSMITH HOSPITAL, DU CANE ROAD ; W12 0NN LONDON
• Région: London › Inner London — West › Kensington & Chelsea and Hammersmith & Fulham
• Type d’activité: Private for-profit entities (excluding Higher or Secondary Education Establishments)
• Contact administratif: Michael Cousins (Mr.)
• Coût total: Aucune donnée